# B3 - Brasil Bolsa Balcão Valuation

Is B3SA3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6Valuation Score 2/6

Below Fair Value

Significantly Below Fair Value

Price-To-Earnings vs Peers

Price-To-Earnings vs Industry

Price-To-Earnings vs Fair Ratio

Analyst Forecast

## Share Price vs Fair Value

What is the Fair Price of B3SA3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: B3SA3 (R$10.23) is trading above our estimate of fair value (R$7.04)

Significantly Below Fair Value: B3SA3 is trading above our estimate of fair value.

## Key Valuation Metric

Which metric is best to use when looking at relative valuation for B3SA3?

Other financial metrics that can be useful for relative valuation.

What is B3SA3's n/a Ratio? | |
---|---|

n/a | 0x |

n/a | n/a |

Market Cap | n/a |

Key Statistics | |
---|---|

Enterprise Value/Revenue | 5.8x |

Enterprise Value/EBITDA | 10.1x |

PEG Ratio | 1.2x |

## Price to Earnings Ratio vs Peers

How does B3SA3's PE Ratio compare to its peers?

Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|

Peer Average | 29.6x | ||

BPAC11 Banco BTG Pactual | 14.8x | 14.8% | R$161.4b |

MKTX MarketAxess Holdings | 36.1x | 10.4% | US$10.2b |

S68 Singapore Exchange | 20.6x | 3.6% | S$12.4b |

1111 Saudi Tadawul Group Holding | 46.7x | 11.3% | ر.س27.9b |

B3SA3 B3 - Brasil Bolsa Balcão | 13.1x | 11.2% | R$55.1b |

Price-To-Earnings vs Peers: B3SA3 is good value based on its Price-To-Earnings Ratio (13.1x) compared to the peer average (29.6x).

## Price to Earnings Ratio vs Industry

How does B3SA3's PE Ratio compare vs other companies in the South American Capital Markets Industry?

Price-To-Earnings vs Industry: B3SA3 is expensive based on its Price-To-Earnings Ratio (13.1x) compared to the South American Capital Markets industry average (9.5x).

## Price to Earnings Ratio vs Fair Ratio

What is B3SA3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Fair Ratio | |
---|---|

Current PE Ratio | 13.1x |

Fair PE Ratio | 12.2x |

Price-To-Earnings vs Fair Ratio: B3SA3 is expensive based on its Price-To-Earnings Ratio (13.1x) compared to the estimated Fair Price-To-Earnings Ratio (12.2x).

## Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|

Current | R$10.23 | R$14.31 +39.9% | 9.1% | R$17.00 | R$12.50 | n/a | 13 |

Nov ’25 | R$10.42 | R$14.33 +37.5% | 8.8% | R$17.00 | R$12.50 | n/a | 14 |

Oct ’25 | R$10.71 | R$14.33 +33.8% | 8.8% | R$17.00 | R$12.50 | n/a | 14 |

Sep ’25 | R$12.68 | R$14.40 +13.6% | 8.4% | R$17.00 | R$12.50 | n/a | 14 |

Aug ’25 | R$10.87 | R$14.14 +30.1% | 8.2% | R$16.00 | R$11.40 | n/a | 14 |

Jul ’25 | R$10.47 | R$14.20 +35.6% | 9.2% | R$17.00 | R$11.40 | n/a | 14 |

Jun ’25 | R$10.70 | R$14.66 +37.0% | 10.2% | R$17.00 | R$11.40 | n/a | 14 |

May ’25 | R$10.79 | R$15.00 +39.0% | 8.1% | R$17.00 | R$13.10 | n/a | 14 |

Apr ’25 | R$11.77 | R$15.46 +31.4% | 8.4% | R$17.00 | R$13.10 | n/a | 14 |

Mar ’25 | R$12.42 | R$15.96 +28.5% | 10.1% | R$19.00 | R$13.10 | n/a | 14 |

Feb ’25 | R$13.29 | R$16.10 +21.1% | 9.5% | R$19.00 | R$13.50 | n/a | 14 |

Jan ’25 | R$14.55 | R$16.03 +10.1% | 9.7% | R$19.00 | R$13.50 | n/a | 14 |

Dec ’24 | R$13.53 | R$15.67 +15.8% | 10.6% | R$18.00 | R$13.50 | n/a | 14 |

Nov ’24 | R$11.55 | R$15.98 +38.4% | 9.7% | R$18.00 | R$14.00 | R$10.42 | 12 |

Oct ’24 | R$12.29 | R$16.15 +31.4% | 8.5% | R$18.00 | R$14.00 | R$10.71 | 12 |

Sep ’24 | R$12.98 | R$15.74 +21.3% | 10.2% | R$18.00 | R$12.50 | R$12.68 | 15 |

Aug ’24 | R$14.74 | R$15.19 +3.1% | 10.5% | R$18.00 | R$12.50 | R$10.87 | 15 |

Jul ’24 | R$14.61 | R$14.86 +1.7% | 11.8% | R$18.00 | R$12.50 | R$10.47 | 15 |

Jun ’24 | R$14.30 | R$14.39 +0.6% | 9.7% | R$18.00 | R$12.50 | R$10.70 | 15 |

May ’24 | R$11.68 | R$13.93 +19.3% | 9.5% | R$16.00 | R$11.50 | R$10.79 | 16 |

Apr ’24 | R$10.35 | R$14.37 +38.8% | 9.7% | R$16.00 | R$11.50 | R$11.77 | 16 |

Mar ’24 | R$10.50 | R$14.87 +41.6% | 7.9% | R$17.00 | R$12.00 | R$12.42 | 16 |

Feb ’24 | R$12.91 | R$15.15 +17.4% | 8.1% | R$17.00 | R$12.80 | R$13.29 | 14 |

Jan ’24 | R$13.21 | R$15.22 +15.2% | 9.6% | R$18.00 | R$12.80 | R$14.55 | 14 |

Dec ’23 | R$12.41 | R$15.63 +25.9% | 10.4% | R$18.00 | R$12.80 | R$13.53 | 15 |

Nov ’23 | R$15.12 | R$16.18 +7.0% | 13.2% | R$21.05 | R$12.90 | R$11.55 | 15 |

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.